98 results
CORRESP
IMCR
Immunocore Holdings plc
15 Jan 21
Correspondence with SEC
12:00am
in vitro toxicity platform”. Alternatively, please revise this statement to be more specific concerning the nature of the platform.
Response … sufficient information to enable users of financial statements to understand the nature, amount, timing and uncertainty of revenue and cash flows
F-1/A
EX-10.19
IMCR
Immunocore Holdings plc
1 Feb 21
Registration statement (foreign) (amended)
6:21am
(b), then the party required to make such disclosure shall, so far as reasonably practicable, consult with the other as to the form, nature and extent … commitment of any nature whatsoever (whether or not in writing) made or given by or on behalf of the other party which is not expressly set out
F-1/A
EX-10.19
IMCR
Immunocore Holdings plc
3 Feb 21
Registration statement (foreign) (amended)
5:22pm
as to the form, nature and extent of the disclosure before making it.
COSTS
Each party shall pay its own costs and expenses in relation to the negotiation … , promise or other commitment of any nature whatsoever (whether or not in writing) made or given by or on behalf of the other party which
UPLOAD
IMCR
Immunocore Holdings plc
14 Dec 20
Letter from SEC
12:00am
the nature of the platform.
Advantages of our ImmTAC Platform vs. Other Cancer Immunotherapies, page 129
11. Please revise your disclosure … as applicable to clearly disclose
sufficient
information to enable users of financial statements to understand the
nature, amount,
timing
10-K
2023 FY
EX-10.14
IMCR
Immunocore Holdings plc
28 Feb 24
Annual report
7:33am
to any expenditure or obligations of an unusually onerous or exceptional nature without the prior consent of THE COMPANY.
THE COMPANY may require you … premises at Milton Park, Abingdon, Oxford or such other location as THE COMPANY reasonably directs. The nature of your job is such that you may also
F-1
EX-10.1
u3kte2
15 Jan 21
Registration statement (foreign)
4:57pm
6-K
EX-99.1
rtaexr6bywwuz
11 Aug 21
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:00am
6-K
EX-99.1
qe4nvjsmhb5h
12 May 21
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:00am
6-K
EX-99.2
bvvsnf5k 9tt7
11 May 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:08am
6-K
EX-99.2
8co2eo9 7ko6gr
12 May 21
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:00am
DRS/A
EX-10.9
ud2nwfkiaescsbw
22 Dec 20
Draft registration statement (amended)
12:00am
F-1
EX-10.10
e64gxn 3b277oj3nrgas
15 Jan 21
Registration statement (foreign)
4:57pm
6-K
EX-99.2
a0lw8q0yt88bi21wi
10 May 23
Current report (foreign)
7:27am
6-K
EX-99.2
wszhtok92
11 Aug 21
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:00am
6-K
EX-99.1
bh1ozbhjbpdd0se1iqa4
10 Nov 21
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:01am
F-1/A
EX-10.12
v5irsvl310l00ex
1 Feb 21
Registration statement (foreign) (amended)
6:21am
F-1/A
EX-10.12
qon4dm03y 2s98z
3 Feb 21
Registration statement (foreign) (amended)
5:22pm
6-K
EX-99.1
i4k7eh9yuy ko9g
11 May 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:08am
6-K
EX-99.4
26r2kco 6f1uazml
9 Nov 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:15am
10-Q
3thdgcqm
8 May 24
Quarterly report
7:00am